ATE383159T1 - Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe - Google Patents

Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Info

Publication number
ATE383159T1
ATE383159T1 AT01959195T AT01959195T ATE383159T1 AT E383159 T1 ATE383159 T1 AT E383159T1 AT 01959195 T AT01959195 T AT 01959195T AT 01959195 T AT01959195 T AT 01959195T AT E383159 T1 ATE383159 T1 AT E383159T1
Authority
AT
Austria
Prior art keywords
neuroprotective agents
sedative
sedating barbiturate
barbiturate compounds
compounds
Prior art date
Application number
AT01959195T
Other languages
German (de)
English (en)
Inventor
Daniel Moros
Barrie Levitt
Avraham Yacobi
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Application granted granted Critical
Publication of ATE383159T1 publication Critical patent/ATE383159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01959195T 2000-07-26 2001-07-26 Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe ATE383159T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22167200P 2000-07-26 2000-07-26

Publications (1)

Publication Number Publication Date
ATE383159T1 true ATE383159T1 (de) 2008-01-15

Family

ID=22828824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01959195T ATE383159T1 (de) 2000-07-26 2001-07-26 Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Country Status (13)

Country Link
EP (1) EP1311270B1 (enExample)
JP (1) JP5047442B2 (enExample)
CN (2) CN100522172C (enExample)
AT (1) ATE383159T1 (enExample)
AU (2) AU2001280778B2 (enExample)
BR (1) BR0112775A (enExample)
CA (1) CA2416535C (enExample)
DE (1) DE60132337T2 (enExample)
ES (1) ES2300349T3 (enExample)
IL (3) IL154060A0 (enExample)
MX (1) MXPA03000824A (enExample)
PT (1) PT1311270E (enExample)
WO (1) WO2002007729A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
WO2002007729A1 (en) * 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1485101A4 (en) * 2002-01-30 2006-04-12 Taro Pharma Ind NON-SURFACTANT BARBITIC ACID DERIVATIVES
ATE546136T1 (de) 2002-10-11 2012-03-15 Baxter Int Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
JP4739760B2 (ja) * 2002-12-11 2011-08-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド バルビツール酸誘導体を使用する運動障害の治療方法
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
RU2370266C2 (ru) * 2007-12-21 2009-10-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ общего обезболивания
EP2755945A1 (en) * 2011-09-12 2014-07-23 Council of Scientific & Industrial Research ARYLATED beta-DICARBONYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
US11016084B2 (en) 2015-10-05 2021-05-25 The University Of North Carolina At Chapel Hill Decoding methods for multiplexing assays and associated fluidic devices, kits, and solid supports

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
WO2002007729A1 (en) * 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents

Also Published As

Publication number Publication date
CA2416535C (en) 2010-11-16
IL165017A0 (en) 2005-12-18
JP2004517808A (ja) 2004-06-17
WO2002007729A1 (en) 2002-01-31
IL154060A (en) 2013-05-30
BR0112775A (pt) 2003-12-30
ES2300349T3 (es) 2008-06-16
AU2001280778B2 (en) 2004-09-02
AU8077801A (en) 2002-02-05
CN100522172C (zh) 2009-08-05
DE60132337D1 (de) 2008-02-21
PT1311270E (pt) 2008-04-15
EP1311270A4 (en) 2006-04-12
CA2416535A1 (en) 2002-01-31
JP5047442B2 (ja) 2012-10-10
HK1100814A1 (en) 2007-09-28
MXPA03000824A (es) 2004-11-01
IL154060A0 (en) 2003-07-31
CN1872067A (zh) 2006-12-06
DE60132337T2 (de) 2009-02-12
WO2002007729A9 (en) 2002-08-08
EP1311270A1 (en) 2003-05-21
CN1329032C (zh) 2007-08-01
CN1461219A (zh) 2003-12-10
EP1311270B1 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
DE60132337D1 (de) Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
BR0314898A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
AR034858A1 (es) Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AU7315301A (en) Compounds and compositions for delivering active agents
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
BR9812492A (pt) Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
ATE431149T1 (de) Analoge der barbitursäure als therapeutische wirkstoffe
DE60024414T2 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
IL162614A (en) Alpha tocopherol esters for use in treating culture-borne cell disease by aerosol administration
DE60022895D1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler
NZ509172A (en) Antimalarial agents
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
BRPI9916820A2 (pt) Formulações farmacêuticas
BR0111669A (pt) Novos compostos
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
ATE173926T1 (de) Arzneizusammensetzungen enthaltend tandospiron oder seine analoge
MY153713A (en) A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties